OUR COMMITMENT TO CYBERSECURITY
To protect the devices, products, and systems that connect patients to healthcare professionals and institutions, we take a broad and deep approach to ensuring safety and security. Our cybersecurity program is built on four pillars. Because technology and threats continue to evolve, we are constantly evaluating and adapting security measures with the goal of ensuring our patients receive the highest quality care. Read more about Our Commitment to Cybersecurity.
INFANT FORMULA MARKETING
Abbott believes that proper nutrition is the foundation for living the best life possible. We aim to make every stage of life a healthy one – and we share this goal with many others around the world. That's why our nutrition business is dedicated to developing science-based nutrition products for people of all ages. We believe that breast milk is the best source of nutrition for infants and support the World Health Organization's goal of increasing breastfeeding rates. Read more about Abbott Infant Formula Marketing.
POSITION STATEMENT ON HUMAN RIGHTS
Abbott believes in the dignity of every human being and respects individual rights as set forth in the United Nations' Universal Declaration of Human Rights and Guiding Principles on Business and Human Rights. While governments have the primary responsibility for respecting, protecting, promoting and fulfilling the human rights of their citizens, Abbott recognizes that companies play a supporting role in promoting human rights within their spheres of influence. We contribute to the fulfillment of human rights through compliance with laws and regulations wherever we operate, as well as through our policies and programs. Read more about our position statement.
Stakeholder Engagement Policy
Abbott is an active participant in the global dialogue on health and well-being. We recognize that listening to our stakeholders and responding thoughtfully to their concerns and ideas are vital to our success as a business, and to our progress as a global corporate citizen. Understanding stakeholder insights helps us to develop new products to address unmet health needs; educate patients; engage healthcare professionals; and understand how and where our company can make a real difference. Read more about our policy.
Position Statement on Tax
Abbott is committed to responsible tax management and transparency across our global operations. With businesses operating in more than 150 countries, our tax contribution is substantial and similarly global in scope, and includes corporate, sales, customs and employee taxes that make a significant contribution to societies around the world. Read more about our position statement.
QUALITY MEMBERSHIPS, PARTNERSHIPS, AND EVENTS
Consumers trust Abbott products to help them live their best possible lives through better health. We do not take this responsibility lightly. We are fully committed to delivering products with the highest standards of quality, safety and performance. Our quality culture is embedded in everything we do. As part of our efforts to remain up to date with product quality and safety developments, we monitor evolving regulatory requirements and industry practices through our involvement in trade associations, patient groups and other organizations. Read more about our partnerships.
California Compliance Program
A growing number of laws in the United States require greater transparency in the relationships between our industry and individuals and entities involved in providing health care. These laws impose various combinations of code of conduct restrictions on activities involving health care professionals and health care organizations and tracking and reporting of payments and transfers of value provided. Abbott policies require compliance with all such applicable laws, including the federal Sunshine Act as well as state laws in California, Connecticut, Massachusetts, Nevada, and Vermont.
Data Transfer Privacy Statement
International Transfers. By using this site, you consent to the collection, storage, and processing of your information in the United States and in any country to which we may transfer your information in the course of our business operations. Where required, Abbott Laboratories has implemented appropriate cross-border transfer solutions to provide adequate protection for transfers of certain personal information, including, but not limited to, the European Commission’s Standard Contractual Clauses.
California Transparency in Supply Chains Act
Abbott believes in being a socially responsible company and doing what is right, not just by our customers, but by the world in which we live. Abbott is committed to safe and fair working conditions, beyond our employees and the stores in which our products are sold, but also extending to the partners in our supply chain. Abbott always has had and will continue to have a zero tolerance policy regarding human trafficking and slavery. Abbott has a global policy against trafficking and slavery in supply chains. Abbott engages in verification of product supply chains to evaluate and address risks of human trafficking and slavery. Specifically, Abbott utilizes a supplier classification model to determine appropriate activity level to assess risk. A supplier may receive a letter, a survey or an on-site audit (usually announced ahead of time) based on this model. Information received from the supplier is then assessed to determine whether to take further steps. Currently, this verification is conducted by Abbott employees in its Global Purchasing Services Compliance department.
Abbott’s Supplier Guidelines state our expectations to suppliers conducting business with Abbott that they are prohibited from engaging in illegal behavior, including human trafficking and slavery. Abbott’s internal Code of Business Conduct also incorporates standards prohibiting slavery/trafficking or engaging in illegal behavior. Abbott requires direct suppliers to certify that materials incorporated into Abbott’s products comply with local and national laws of the country or countries in which they are doing business. Certifications are also obtained from suppliers that they comply with standards as outlined in our Supplier Guidelines. Abbott maintains internal accountability standards and procedures for both employees and contractors failing to meet company standards regarding slavery and trafficking. In particular, Abbott employees worldwide train annually on Abbott’s Code of Business Conduct. Likewise, all contractors assigned to Abbott are required to review and abide by Abbott’s Code of Business Conduct.
Employees and contractors assigned to Abbott who fail to abide by Abbott’s Code of Business Conduct may be subject to reprimand or other adverse consequences, up to and including termination of employment or assignment. Abbott provides training to its employees and management who have direct responsibility for supply chain management, regarding human trafficking and slavery, particularly with respect to mitigating risks within the supply chains of products.
U.S. Postmarketing Commitments
Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about a product’s safety, effectiveness, and/or optimal use. These postmarketing commitment (PMC) studies build upon the data that was submitted for approval.
This website contains Abbott’s U.S. postmarketing commitments. Click here to view Abbott’s PMC Summary Table.
Our PMC Summary Table includes all active postmarketing commitments and provides the following information, organized alphabetically by product name:
Please note that the status and/or number of Abbott’s postmarketing commitments shown on the FDA website may differ from the information displayed on this site based on the timing of content review and website updates. The status categories used in the PMC Summary Table are consistent with categories used by the FDA.
Information about Abbott’s PMCs will be updated twice a year, to reflect new commitments as well as the progress we have made in fulfilling our existing postmarketing commitments. Once the FDA determines a PMC is fulfilled, or they release Abbott from a commitment, or if Abbott terminates a study before completion date, those PMCs will be removed from our PMC Summary Table.
The PMCs listed in the PMC Summary Table include preclinical (nonhuman), clinical (medical), and epidemiological studies that Abbott has agreed to conduct to gather additional information about the safe and effective use of our approved products. This website does not contain technical chemistry, manufacturing and controls (CMC) PMCs, or PMCs issued by FDA for products where Abbott does not hold the US regulatory approval.
Note: All data reflects Abbott activities in 2012. Some content has been adjusted to remove data specific to AbbVie, which became a separate company on Jan. 1, 2013.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.